Geode Capital Management’s Amylyx Pharmaceuticals AMLX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $10.9M | Buy |
1,692,413
+886,252
| +110% | +$5.68M | ﹤0.01% | 2311 |
|
|
2025
Q1 | $2.85M | Buy |
806,161
+238,258
| +42% | +$844K | ﹤0.01% | 2913 |
|
|
2024
Q4 | $2.15M | Buy |
567,903
+16,864
| +3% | +$63.8K | ﹤0.01% | 3096 |
|
|
2024
Q3 | $1.79M | Buy |
551,039
+82,173
| +18% | +$266K | ﹤0.01% | 3164 |
|
|
2024
Q2 | $891K | Sell |
468,866
-597,379
| -56% | -$1.14M | ﹤0.01% | 3345 |
|
|
2024
Q1 | $3.03M | Buy |
1,066,245
+35,529
| +3% | +$101K | ﹤0.01% | 2941 |
|
|
2023
Q4 | $15.2M | Buy |
1,030,716
+48,648
| +5% | +$716K | ﹤0.01% | 2076 |
|
|
2023
Q3 | $18M | Buy |
982,068
+44,071
| +5% | +$807K | ﹤0.01% | 1887 |
|
|
2023
Q2 | $20.2M | Buy |
937,997
+47,015
| +5% | +$1.01M | ﹤0.01% | 1848 |
|
|
2023
Q1 | $26.1M | Buy |
890,982
+37,069
| +4% | +$1.09M | ﹤0.01% | 1624 |
|
|
2022
Q4 | $31.6M | Buy |
853,913
+218,357
| +34% | +$8.07M | ﹤0.01% | 1472 |
|
|
2022
Q3 | $17.9M | Buy |
635,556
+404,139
| +175% | +$11.4M | ﹤0.01% | 1816 |
|
|
2022
Q2 | $4.46M | Buy |
231,417
+41,267
| +22% | +$795K | ﹤0.01% | 2760 |
|
|
2022
Q1 | $2.44M | Buy |
+190,150
| New | +$2.44M | ﹤0.01% | 3159 |
|